Amphastar Pharmaceuticals/$AMPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Ticker
$AMPH
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
2,028
ISIN
US03209R1032
Website
AMPH Metrics
BasicAdvanced
$1.1B
8.11
$2.77
0.78
-
Price and volume
Market cap
$1.1B
Beta
0.78
52-week high
$52.05
52-week low
$22.29
Average daily volume
509K
Financial strength
Current ratio
2.954
Quick ratio
1.92
Long term debt to equity
85.795
Total debt to equity
86.856
Interest coverage (TTM)
5.90%
Profitability
EBITDA (TTM)
247.928
Gross margin (TTM)
50.50%
Net profit margin (TTM)
19.38%
Operating margin (TTM)
26.65%
Effective tax rate (TTM)
18.02%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
7.60%
Return on equity (TTM)
19.90%
Valuation
Price to earnings (TTM)
8.115
Price to revenue (TTM)
1.483
Price to book
1.42
Price to tangible book (TTM)
6.41
Price to free cash flow (TTM)
7.213
Free cash flow yield (TTM)
13.86%
Free cash flow per share (TTM)
311.12%
Growth
Revenue change (TTM)
8.05%
Earnings per share change (TTM)
-4.83%
3-year revenue growth (CAGR)
17.09%
10-year revenue growth (CAGR)
12.68%
3-year earnings per share growth (CAGR)
19.48%
10-year earnings per share growth (CAGR)
28.55%
What the Analysts think about AMPH
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
Bulls say / Bears say
Amphastar Pharmaceuticals reported a 23% increase in net revenues for Q1 2024, reaching $171.8 million, indicating strong financial performance. (finance.yahoo.com)
The acquisition of BAQSIMI® from Eli Lilly in April 2023 for over $1 billion expands Amphastar's product portfolio into the diabetes market, potentially driving future revenue growth. (wikipedia.org)
Institutional investors have shown increased interest, with Pacer Advisors Inc. acquiring over 1.3 million shares in Q4 2024, reflecting confidence in the company's prospects. (defenseworld.net)
Piper Sandler downgraded Amphastar Pharmaceuticals to a 'Neutral' rating in February 2025, suggesting potential concerns about the company's future performance. (defenseworld.net)
The company's gross margin decreased to 52.4% in Q1 2024 from 52.7% the previous year, indicating potential challenges in maintaining profitability. (finance.yahoo.com)
Amphastar's stock price declined by 35.7% since the beginning of 2025, underperforming the S&P 500's decline of 4.7%, which may reflect investor concerns. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AMPH Financial Performance
Revenues and expenses
AMPH Earnings Performance
Company profitability
AMPH News
AllArticlesVideos
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Accesswire·2 months ago
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Accesswire·2 months ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amphastar Pharmaceuticals stock?
Amphastar Pharmaceuticals (AMPH) has a market cap of $1.1B as of July 10, 2025.
What is the P/E ratio for Amphastar Pharmaceuticals stock?
The price to earnings (P/E) ratio for Amphastar Pharmaceuticals (AMPH) stock is 8.11 as of July 10, 2025.
Does Amphastar Pharmaceuticals stock pay dividends?
No, Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Amphastar Pharmaceuticals dividend payment date?
Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals (AMPH) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.